Drugs / Magtrace
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06868238 | Aug 2026 → Jun 2029 | ductal breast carcinoma in situ | University of Florida | Suspended | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06273501 | Mar 2022 → Dec 2024 | metastatic malignant neoplasm in the lymph nodes, vulva cancer | Sahlgrenska University Hospital | Unknown | No outcome recorded |
| — | NCT05625698 | Oct 2021 → Oct 2023 | breast cancer | Vastra Gotaland Region | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MagTrace | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05625698 ↗ |
| Known as | superparamagnetic oxide (SPIO) | “Magtrace, or superparamagnetic oxide (SPIO), was developed in 2018.” NCT06868238 ↗ |
| Modality | Diagnostic / imaging agent | “a novel iron based lymphatic mapping agent” NCT06868238 ↗ |
| Route | Other | “Participants will receive a single injection of Magtrace into the breast during their mastectomy.” NCT06868238 ↗ |